Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HIND

Vyome Holdings Inc

Apr 30 • 11:12AM ET

2.06

+0.02 0.98 %

Healthcare • Biotechnology • USA • Nano • NASD

Held by: VXF

Scroll to Statements

Index	-	P/E	0.03	EPS (ttm)	63.65	Insider Own	52.82%	Shs Outstand	5.92M	Perf Week	-8.85%
Market Cap	14.46M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	0.00%	Shs Float	3.31M	Perf Month	-4.19%
Enterprise Value	10.83M	PEG	-	EPS next Q	-	Inst Own	1.50%	Short Float	4.35%	Perf Quarter	-3.74%
Income	-10.82M	P/S	5.95	EPS this Y	-	Inst Trans	3.72%	Short Ratio	1.25	Perf Half Y	-62.75%
Sales	2.43M	P/B	4.99	EPS next Y	-	ROA	-191.00%	Short Interest	0.14M	Perf YTD	-40.12%
Book/sh	0.41	P/C	2.90	EPS next 5Y	91.02%	ROE	-988.12%	52W High	56.38 -96.35%	Perf Year	-93.91%
Cash/sh	0.71	P/FCF	-	EPS past 3/5Y	98.04% 93.71%	ROIC	-442.88%	52W Low	1.75 17.71%	Perf 3Y	-99.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-69.47% -50.98%	Gross Margin	54.18%	Volatility	5.19% 7.00%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	4.46	EPS Y/Y TTM	104.36%	Oper. Margin	-252.00%	ATR (14)	0.15	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.99	Sales Y/Y TTM	-69.70%	Profit Margin	-445.77%	RSI (14)	38.67	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.99	EPS Q/Q	99.91%	SMA20	-6.34%	Beta	1.40	Target Price	15.00
Payout	-	Debt/Eq	0.01	Sales Q/Q	-97.98%	SMA50	-15.56%	Rel Volume	0.12	Prev Close	2.04
Employees	18	LT Debt/Eq	0.00	Earnings	Mar 26 BMO	SMA200	-59.86%	Avg Volume	115.21K	Price	2.06
IPO	Oct 06, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	-2736.36% -	Trades		Volume	4,443	Change	0.98%

Apr-22-26 08:00AM	Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 (Business Wire)
Apr-06-26 08:00AM	Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026 (Business Wire)
Mar-30-26 07:00PM	Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com) +5.39%
Mar-26-26 08:00AM	Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase (Business Wire)
Feb-24-26 08:00AM	Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company (Business Wire) +8.28%
09:00AM	Loading…
Feb-18-26 09:00AM	Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity (Business Wire) +6.84%
Feb-11-26 07:00AM	Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months (Business Wire)
Feb-02-26 07:00AM	Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results (Business Wire) +14.58%
Jan-27-26 08:00AM	Independent Analyst Values Vyomes VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study (Business Wire)
Dec-22-25 08:00AM	Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company (Business Wire) +5.43%
Dec-08-25 08:00AM	Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval (Business Wire) +14.37%
Nov-25-25 07:00AM	Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program (Business Wire)
Nov-18-25 07:00AM	Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing (Business Wire)
Nov-04-25 09:04AM	Vyome Holdings Announces Results of Annual Shareholder Meeting (Business Wire)
Sep-29-25 07:00AM	Vyome Holdings Acquires MIT AI Spinout Oculo Health (Business Wire)
07:00AM	Loading…
Sep-17-25 07:00AM	Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity (Business Wire)
Sep-09-25 08:30AM	Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies (Business Wire)
Sep-04-25 08:30AM	Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity (Business Wire) -9.06%
Aug-21-25 07:00AM	Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio (Business Wire) +21.91%
Aug-18-25 08:30AM	Vyome Announces Strategic Review of Livechain (OTCID: LICH) (Business Wire) -37.64%
Aug-15-25 02:57PM	Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market (Investing.com) -10.71%
08:00AM	Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell (Business Wire)
Aug-14-25 07:18PM	Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow (Business Wire) +22.50%

Vyome Holdings, Inc. engages in the development of immuno-inflammatory assets. It focuses on therapeutic solutions that target formulations for site-targeted applications. The company was founded on January 2, 2008 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HIND

Vyome Holdings Inc

Upgrade your Finviz experience